Spinocerebellar Ataxia Clinical Trials

Find Spinocerebellar Ataxia Clinical Trials Near You

TreatHSP/SPAX Master Protocol: Adaptive Platform for Longitudinal Progression, Biomarkers and Pathophysiology in Ataxias, Hereditary Spastic Paraplegias and Spastic Ataxias (TreatHSP/SPAX)

Status: Recruiting
Location: See all (29) locations...
Study Type: Observational
SUMMARY

Ataxias, hereditary spastic paraplegias (HSP), and spastic ataxias (collectively referred to as SPAX diseases) are rare neurological conditions that cause progressive problems with walking, balance, coordination, and daily activities. Although many SPAX diseases are caused by specific genetic changes, there is still limited knowledge about how symptoms develop over time, how fast the diseases progress, and which clinical or biological measures best reflect meaningful changes for patients. The TreatHSP Master Protocol establishes an adaptive natural history study platform designed to improve the understanding of SPAX diseases across all ages and disease stages. Within this platform, the TreatHSP/SPAX study serves as the core natural history study, providing a shared framework for long-term clinical follow-up, standardized outcome assessments, and biosample collection. Participants enrolled in TreatHSP/SPAX are followed over time to document disease progression using clinical examinations, patient- and caregiver-reported outcomes, digital movement measures, imaging, and biological samples. In addition to this core dataset, the TreatHSP Platform allows optional, disease- or hypothesis-specific substudies to be added over time in selected participant groups. These additional assessments are introduced under the same master protocol, without creating separate stand-alone studies. The overall goal of the TreatHSP Master Protocol is to generate high-quality natural history data, identify sensitive and patient-relevant outcome measures, and support the development of future therapies for ataxias, hereditary spastic paraplegias, and spastic ataxias.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: t
View:

⁃ \- Age 5 or older

⁃ Cohort 1: Affected

• Clinical diagnosis of neurodevelopmental or neurodegenerative ataxia, spastic ataxia, HSP or related phenotype AND

• Alternative causes of phenotype excluded

⁃ Cohort 2: Presymptomatic mutation carriers

⁃ \- Premanifest mutation carrier of (likely) pathogenic variant(s) in a disease gene associated with ataxia, spastic ataxia, HSP or related phenotype

⁃ Cohort 3: Family controls - 1st or 2nd degree relative of a person with a clinical or genetic diagnosis of ataxia, spastic ataxia, HSP or related phenotype

⁃ Cohort 4: Community controls

⁃ \- Healthy individual unrelated to a person with neurodevelopmental or neurodegenerative ataxia, spastic ataxia, HSP or related phenotype

Locations
Other Locations
Austria
Medical University Innsbruck, Department of Neurology
RECRUITING
Innsbruck
France
Paris Brain Institute ICM CRMR Neurogénétique, Hôpital de la Pitié-Salpêtrière Sorbonne Université UM75 Inserm U1127 CNRS UMR 7225 47 boulevard de l'Hôpital, CS21414
RECRUITING
Paris
Germany
Ruhr University Bochum, Institute for Neuroinformatics (INI)
RECRUITING
Bochum
German Center for Neurodegenerative Diseases (DZNE) Bonn University Hospital Bonn Clinic for Parkinson's, sleep and movement disorders
RECRUITING
Bonn
German Center for Neurodegenerative Diseases (DZNE) Dresden; University Hospital Carl Gustav Carus Clinic and Polyclinic for Neurology
RECRUITING
Dresden
University Hospital Erlangen, Department of Neurology
RECRUITING
Erlangen
University Hospital Essen, Department of Pediatric Neurology / Institute of Human Genetics
RECRUITING
Essen
German Center for Neurodegenerative Diseases (DZNE) Göttingen
RECRUITING
Göttingen
University Hospital Göttingen, Department of Neurology
RECRUITING
Göttingen
University Medical Centre Göttingen, Clinic for Paediatric and Adolescent Medicine
RECRUITING
Göttingen
Heidelberg University Hospital, Center for Child and Adolescent Medicine
RECRUITING
Heidelberg
University Hospital Heidelberg, Department of Neurology
RECRUITING
Heidelberg
University Hospital Schleswig-Holstein , Department of Neurology
RECRUITING
Kiel
German Center for Neurodegenerative Diseases (DZNE) Magdeburg, University Hospital Magdeburg, Department of Neurology
RECRUITING
Magdeburg
German Center for Neurodegenerative Diseases (DZNE) Munich, Munich University Hospital LMU, Department of Neurology
RECRUITING
München
Klinikum Vest GmbH, Treatment Center Knappschafts Hospital Recklinghausen, NeuroCentrum - Department of Neurology, Stroke Unit and Early Rehabilitation
RECRUITING
Recklinghausen
University Hospital and Faculty of Medicine Tübingen, Clinic for Paediatrics and Adolescent Medicine
RECRUITING
Tübingen
University Hospital and Faculty of Medicine Tübingen, Neurology with a Focus on Neurodegenerative Diseases
RECRUITING
Tübingen
Ireland
Tallaght University Hospital, Neurology
RECRUITING
Dublin
Italy
IRCCS Fondazione Stella Maris, MEDMOL - Molecular Medicine, Neurogenetics and Neuromuscular Diseases
RECRUITING
Calambrone
Associazione La Nostra Famiglia - IRCCS Eugenio Medea
RECRUITING
Conegliano
University of Pisa, Azienda Ospedaliero Universitaria Pisana, Neurology
RECRUITING
Pisa
IRCCS Istituto Ospedale Pediatrico Bambino Gesù, Translational Pediatrics and Clinical Genetics
RECRUITING
Roma
Università Cattolica del Sacro Cuore, Department of Neuroscience
RECRUITING
Roma
Netherlands
Radboud university medical center - Radboundumc, University Medical Center
RECRUITING
Nijmegen
Poland
University Hospital in Kraków, Neurology Clinical Department
RECRUITING
Krakow
Spain
Hospital Sant Joan de Déu Barcelona, Neuromuscular Diseases Unit
RECRUITING
Barcelona
Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron University Hospital - Neurology Department
RECRUITING
Barcelona
University Hospital Marqués de Valdecilla-IDIVAL, Department of Neurology
RECRUITING
Santander
Contact Information
Primary
Perdita Beck, Study coordinator
Perdita.Beck@med.uni-heidelberg.de
+49 6221 56-38121
Time Frame
Start Date: 2024-07-16
Estimated Completion Date: 2035-12-31
Participants
Target number of participants: 4000
Treatments
Affected
Clinical diagnosis of neurodevelopmental or neurodegenerative ataxia, spastic ataxia, HSP and alternative cause of phenotype excluded
Presymptomatic mutation carrier
Premanifest mutation carrier of (likely) pathogenic variant(s) in a disease gene associated with ataxia, spastic ataxia, HSP or related phenotype
Family control
1st or 2nd degree relative of a person with a clinical or genetic diagnosis of ataxia, spastic ataxia, HSP or related phenotype (group: Affected)
Community control
Healthy individual unrelated to a person with neurodevelopmental or neurodegenerative ataxia, spastic ataxia, HSP or related phenotype
Sponsors
Collaborators: European Reference Network for Rare Neurological Diseases (ERN-RND), Horizon Europe, Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR), National Institute of Neurological Disorders and Stroke (NINDS), University Hospital Heidelberg
Leads: Heidelberg University

This content was sourced from clinicaltrials.gov